FibroBiologics, Inc. (FBLG) Financial Statements (2026 and earlier)

Company Profile

Business Address 9350 KIRBY DRIVE
HOUSTON, TX 77054
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,8944,8678,8458,66713,9857,827
Cash and cash equivalent4,8944,8678,8458,66713,9857,827
Prepaid expense1,4553731,333642225353
Other current assets   181818
Total current assets:6,3495,24010,1789,32714,2288,198
Noncurrent Assets
Operating lease, right-of-use asset2,3802,5482,7141,2851,3931,499
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization842908967814824772
Other undisclosed noncurrent assets484848   
Total noncurrent assets:3,2703,5043,7292,0992,2172,271
TOTAL ASSETS:9,6198,74413,90711,42616,44510,469
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9451,0691,8011,4172,6971,179
Accrued liabilities 250250,000250,000250  
Other undisclosed accounts payable and accrued liabilities695(248,931)(248,199)1,1672,6971,179
Deferred revenue      241
Debt 4,5738,0665,8399,168115
Other undisclosed current liabilities8141,0801,0979558615,142
Total current liabilities:1,7596,72210,9648,21112,7266,677
Noncurrent Liabilities
Liabilities, other than long-term debt1,7041,8972,0838659841,055
Operating lease, liability1,7041,8972,0838659841,055
Total noncurrent liabilities:1,7041,8972,0838659841,055
Total liabilities:3,4638,61913,0479,07613,7107,732
Equity
Equity, attributable to parent6,1561258602,3502,7352,737
Common stock1     
Additional paid in capital60,31951,04546,00242,83438,25335,156
Accumulated deficit(54,164)(50,920)(45,142)(40,484)(35,518)(32,419)
Total equity:6,1561258602,3502,7352,737
TOTAL LIABILITIES AND EQUITY:9,6198,74413,90711,42616,44510,469

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues3293373   
Gain (loss) on disposition of assets for financial service operations3293373(83)  
Gross profit:3293373   
Operating expenses(2,590)(5,038)(4,490)(4,531)(3,712)(3,352)
Other undisclosed operating income (loss)(329)(33)(73)83  
Operating loss:(2,590)(5,038)(4,490)(4,531)(3,712)(3,352)
Nonoperating income (expense)(654)(740)5099(1,680)2,852
Investment income, nonoperating25735099 79
Interest and debt expense    1,921(5)
Other undisclosed loss from continuing operations before equity method investments, income taxes (204)     
Net loss:(3,448)(5,778)(4,440)(4,432)(3,471)(505)
Other undisclosed net income (loss) attributable to parent204 (218)(534)3725
Net loss available to common stockholders, diluted:(3,244)(5,778)(4,658)(4,966)(3,099)(500)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(3,448)(5,778)(4,440)(4,432)(3,471)(505)
Comprehensive loss, net of tax, attributable to parent:(3,448)(5,778)(4,440)(4,432)(3,471)(505)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: